As a Free StocksGuide user, you can view scores for all 7,033 stocks worldwide.
7 Analysts have issued a Precipio, Inc. forecast:
7 Analysts have issued a Precipio, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 21 21 |
27%
27%
|
|
| Gross Profit | 9.49 9.49 |
45%
45%
|
|
| EBITDA | -1.25 -1.25 |
52%
52%
|
|
| EBIT (Operating Income) EBIT | -2.62 -2.62 |
32%
32%
|
|
| Net Profit | -1.80 -1.80 |
53%
53%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Precipio, Inc. is a cancer diagnostics company, which engages in the development and provision of a platform designed to eradicate the problem of misdiagnosis. Its products include MX-ICP, HemeScreen, and IV-Cell, and services include primary diagnostic, SmartPath, SmartGen, HRM kits and ICP liquid biopsy testing. The company was founded on March 6, 1997 and is headquartered in New Haven, CT.
| Head office | United States |
| CEO | Ilan Danieli |
| Employees | 57 |
| Founded | 1997 |
| Website | www.precipiodx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


